Carbon ion radiotherapy combined with immunotherapy: synergistic anti-tumor efficacy and preliminary investigation of ferroptosis
Open Access
- 30 September 2023
- journal article
- research article
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 72 (12) , 4077-4088
Abstract
Carbon ion radiotherapy (CIRT) may yield satisfactory clinical outcomes for patients who are resistant to radiotherapy. However, the therapeutic impact of carbon ions is still limited in certain recurring or refractory tumors. Therefore, we aimed to evaluate the synergistic anti-tumor effects of immune checkpoint inhibitors (ICIs) in combination with CIRT. We then explored the involvement of ferroptosis in a preliminary investigation. A tumor-bearing mouse model was established, and mice were inoculated subcutaneously with B16-OVA cells into the flanks of both hind legs. Mice were assigned to four groups to receive CIRT, ICIs, or combined treatment. Thereafter, we conducted transcriptome sequencing (RNA-seq), bioinformatics analysis, and various immune-related experiments on the available tumor tissues to investigate differences in the synergistic anticancer effects and potential mechanisms across the groups. The combination therapies significantly improved the survival of mice and inhibited tumor growth, both at local and distant sites. Based on bioinformatics and RNA-seq data, immune-related pathways and genes, immune cell infiltration, and the production of cytokines and chemokines were the most enhanced in the combined treatment group compared to other groups. Finally, we identified a potential role for ferroptosis in the development of local anti-tumor synergy during CIRT combination treatment. In conclusion, this study showed that CIRT and ICIs can enhance the anti-tumor immune effects. We also proposed that ferroptosis may induce anti-tumor effects in CIRT combination therapy, offering a unique perspective on its ability to enhance immunotherapy responses.Keywords
Funding Information
- Science and Technology Development Fund of Shanghai Pudong New Area (PKJ2020-Y53)
- Shanghai Sailing Program (22YF1444800)
- Shanghai Natural Science Foundation (22ZR1458700 and 20ZR1453400, 22ZR1458700 and 20ZR1453400)
- the Key Research and Development Program of the Ministry of Science and Technology (2022YFC2401505)
This publication has 38 references indexed in Scilit:
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung CancerNew England Journal of Medicine, 2017
- Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and DiseaseCell, 2017
- The immune contexture in cancer prognosis and treatmentNature Reviews Clinical Oncology, 2017
- DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicityNature Communications, 2017
- PD-1 Restrains Radiotherapy-Induced Abscopal EffectCancer Immunology Research, 2015
- Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancerNature, 2015
- Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2Genome Biology, 2014
- Particle therapy for cancers: a new weapon in radiation therapyFrontiers of Medicine, 2012
- Cancer and Radiation Therapy: Current Advances and Future DirectionsInternational Journal of Medical Sciences, 2012
- Carbon‐ion beam treatment induces systemic antitumor immunity against murine squamous cell carcinomaCancer, 2010